Oruka Therapeutics develops fully human monoclonal antibodies that aim to achieve near‑complete skin clearance in moderate-to-severe plaque psoriasis and psoriatic arthritis with only one or two injections per year. Its lead candidate, ORKA-001, is in a Phase 2b EVERLAST‑B trial targeting ≥90% PASI response, offering a long‑acting, high‑efficacy option for dermatologists, rheumatologists, and healthcare systems.
Funding
$180M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OVGFounders
Product
Problem
Patients with moderate-to-severe plaque psoriasis and psoriatic arthritis often rely on therapies that require frequent administration and achieve only partial skin clearance, leading to ongoing disease burden and reduced quality of life.
Solution
Oruka Therapeutics is developing monoclonal antibodies designed to deliver higher rates of complete disease clearance with a dosing schedule of only one or two injections per year. Their lead candidate, ORKA-001, is being evaluated in a Phase 2b EVERLAST‑B trial for plaque psoriasis. By extending dosing intervals while maintaining or improving efficacy, the approach aims to reduce treatment complexity and improve patient adherence compared with existing biologics.
Target Audience
Primary customers are dermatologists, rheumatologists, and healthcare systems treating patients with moderate-to-severe plaque psoriasis and psoriatic arthritis who seek high‑efficacy, low‑frequency biologic therapies.
Features
- Fully human monoclonal antibody engineered for potent inhibition of key inflammatory pathways in psoriasis and psoriatic arthritis
- Clinical data program targeting ≥90% skin clearance (PASI 90/100) in moderate-to-severe plaque psoriasis
- Ultra‑long‑acting formulation enabling once‑ or twice‑yearly dosing
- Phase 2b EVERLAST‑B trial design with robust efficacy and safety endpoints
- Potential applicability across multiple dermatologic and inflammatory indications beyond psoriasis